Literature DB >> 16379643

Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs.

Bruno H Pypendop1, Jan E Ilkiw.   

Abstract

OBJECTIVE: To determine the pharmacokinetics of ketamine and norketamine in isoflurane-anesthetized dogs. Animals-6 dogs. PROCEDURE: The minimum alveolar concentration (MAC) of isoflurane was determined in each dog. Isoflurane concentration was then set at 0.75 times the individual's MAC, and ketamine (3 mg/kg) was administered IV. Blood samples were collected at various times following ketamine administration. Blood was immediately centrifuged, and the plasma separated and frozen until analyzed. Ketamine and norketamine concentrations were measured in the plasma samples by use of liquid chromatography-mass spectrometry. Ketamine concentration-time data were fitted to compartment models. Norketamine concentration-time data were examined by use of noncompartmental analysis.
RESULTS: The MAC of isoflurane was 1.43 +/- 0.18% (mean +/- SD). A 2-compartment model best described the disposition of ketamine. The apparent volume of distribution of the central compartment, the apparent volume of distribution at steady state, and the clearance were 371.3 +/- 162 mL/kg, 4,060.3 +/- 2,405.7 mL/kg, and 58.2 +/- 17.3 mL/min/kg, respectively. Norketamine rapidly appeared in plasma following ketamine administration and had a terminal half-life of 63.6 +/- 23.9 minutes. A large variability in plasma concentrations, and therefore pharmacokinetic parameters, was observed among dogs for ketamine and norketamine. CONCLUSIONS AND CLINICAL RELEVANCE: In isofluraneanesthetized dogs, a high variability in the disposition of ketamine appears to exist among individuals. The disposition of ketamine may be difficult to predict in clinical patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379643     DOI: 10.2460/ajvr.2005.66.2034

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Influence of prior determination of baseline minimum alveolar concentration (MAC) of isoflurane on the effect of ketamine on MAC in dogs.

Authors:  Giacomo Gianotti; Alexander Valverde; Ron Johnson; Melissa Sinclair; Thomas Gibson; Doris H Dyson
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Plasma concentration, cardiorespiratory and analgesic effects of ketamine-fentanyl infusion in dogs submitted to mastectomy.

Authors:  Rauane Sousa de Moura; Isabela Plazza Bittar; Janainne Hilbig Gomes; Yan Victor Rodrigues de Oliveira; Gladsthon Divino de Sousa Filho; Glauco Cézar Fragola de Faria Soares; Eliana Martins Lima; Leandro Guimarães Franco
Journal:  BMC Vet Res       Date:  2022-06-14       Impact factor: 2.792

3.  Effects of ketamine and lidocaine in combination on the sevoflurane minimum alveolar concentration in alpacas.

Authors:  Patricia Queiroz-Williams; Thomas J Doherty; Anderson F da Cunha; Claudia Leonardi
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

4.  Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Authors:  Laura C Amann; Tobias B Halene; Richard S Ehrlichman; Stephen N Luminais; Nan Ma; Ted Abel; Steven J Siegel
Journal:  Neurobiol Dis       Date:  2009-05-23       Impact factor: 5.996

5.  Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs.

Authors:  Lise Vlerick; Mathias Devreese; Kathelijne Peremans; Robrecht Dockx; Siska Croubels; Luc Duchateau; Ingeborgh Polis
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  Serum concentration of ketamine and antinociceptive effects of ketamine and ketamine-lidocaine infusions in conscious dogs.

Authors:  Ubedullah Kaka; Bullo Saifullah; Adamu Abdul Abubakar; Yong Meng Goh; Sharida Fakurazi; Asmatullah Kaka; Atique Ahmed Behan; Mahdi Ebrahimi; Hui Cheng Chen
Journal:  BMC Vet Res       Date:  2016-09-09       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.